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Abstract
Synaptonemal complex protein 3 (SCP3), a member of Cor1 family, is up-regulated in various cancer cells; however, its
oncogenic potential and clinical significance has not yet been characterized. In the present study, we investigated the
oncogenic role of SCP3 and its relationship with phosphorylated AKT (pAKT) in cervical neoplasias. The functional role of
SCP3 expression was investigated by overexpression or knockdown of SCP3 in murine cell line NIH3T3 and human cervical
cancer cell lines CUMC6, SiHa, CaSki, and HeLa both in vitro and in vivo. Furthermore, we examined SCP3 expression in
tumor specimens from 181 cervical cancer and 400 cervical intraepithelial neoplasia (CIN) patients by immunohistochem-
istry and analyzed the correlation between SCP3 expression and clinicopathologic factors or survival. Overexpression of
SCP3 promoted AKT-mediated tumorigenesis both in vitro and in vivo. Functional studies using NIH3T3 cells demonstrated
that the C-terminal region of human SCP3 is important for AKT activation and its oncogenic potential. High expression of
SCP3 was significantly associated with tumor stage (P= 0.002) and tumor grade (P,0.001), while SCP3 expression was
positively associated with pAKT protein level in cervical neoplasias. Survival times for patients with cervical cancer
overexpressing both SCP3 and pAKT (median, 134.0 months, n= 68) were significantly shorter than for patients with low
expression of either SCP3 or pAKT (161.5 months, n = 108) as determined by multivariate analysis (P= 0.020). Our findings
suggest that SCP3 plays an important role in the progression of cervical cancer through the AKT signaling pathway,
supporting the possibility that SCP3 may be a promising novel cancer target for cervical cancer therapy.
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Introduction
Tumor cells display a variety of antigens including anomalous
expression of cancer/testis-associated antigens (CTAs). CTAs are
restricted in normal tissues to germ cells of the testis, with
occasional expression in female reproductive organs, and are
expressed in histologically different types of malignant human
tumors [1–4]. The tumor restricted expression pattern of CTAs
makes them an interesting target for immunotherapeutic ap-
proaches [3,5]. The role of CTA expression in tumor cells remains
unclear, and thus is an area of active research. Likewise, our results
on the expression of CTAs and their molecular mechanism in
tumor cells may provide better insight into tumorigenesis.
Cor1 family members such as X-linked lymphocyte regulated
protein (XLR), Xlr-related meiosis regulated protein (XMR), and
synaptonemal complex protein 3 (SCP3) are typical CTAs [1].
They are involved in DNA-binding proteins and a structural
component of the synaptonemal complex, which mediates
synapsis, the pairing of homologous chromosomes during meiosis
of germ cells [6]. Notably, male mice deficient for SCP3 are sterile
as a result of massive apoptotic cell death in the testis during
meiotic prophase [6,7]. Although SCP3 is expressed strictly in the
testis and ovary in normal tissues, expression of SCP3 is frequently
observed in various human cancer cells such as acute lympho-
blastic leukemia and non-small cell lung cancer [8,9]. We
previously performed a small pilot study, and found that SCP3
is expressed in various cervical cancer cell lines and a small
number of cervical cancer tissues [10]. However, none of these
studies have provided convincing evidence of the oncogenic
potential of SCP3.
To elucidate the role of SCP3 in tumorigenesis, we examined
the role of these members as potential oncoproteins by conducting
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a series of in vitro and in vivo experiments using both a murine cell
line (NIH3T3) and human cervical cancer cell lines (CUMC6,
SiHa, CaSki, and HeLa). Here, we report that overexpression of
SCP3 induces phenotypic changes characteristic of transformation
both in vitro and in vivo. Furthermore, we analyzed patterns of
SCP3 and pAKT expression by immunohistochemistry in cervical
tissue specimens from patients with cervical intraepithelial
neoplasia (CIN) or invasive cervical carcinoma. The relationships
between protein expression and clinicopathological parameters/
survival of cervical cancer patients were also analyzed, and
demonstrated that SCP3 expression is a prognostic factor for
patients with cervical cancer.
Materials and Methods
Mice and cell lines
Six- to eight-week-old female Balb/c Nude mice were
purchased from Daehan Biolink (Chungbuk, Korea). All animal
procedures were performed under a protocol approved by the
Korea University Institutional Animal Care and Use Committee
(KUIACUC-2009-126). The murine fibroblast cell line NIH3T3
and human cervical cancer cell lines CUMC6, SiHa, CaSki, and
HeLa were purchased from American Type Culture Collection
(ATCC, Manassas, VA) and were grown in Dulbecco’s Modified
Eagle Medium (DMEM) in the presence of 10% fetal bovine
serum (FBS). All cells were cultured in 5% CO2 balanced air at
37uC. The identities of cell lines were confirmed by short tandem
repeat (STR) profiling by IDEXX Laboratories Inc. and used
within 6 months for testing.
Patients and tumor samples
Primary tumor specimens were obtained between 1996 and
2010 from 181 cases of cervical cancer, 301 cases of high grade
cervical intraepithelial neoplasia (CIN), and 99 cases of low
grade CIN undergoing primary surgery at Gangnam Sever-
ance Hospital, Yonsei University College of Medicine. All
patients gave oral and written informed consent. Paraffin
blocks for some of the patients were provided by the Korea
Gynecologic Cancer Bank through the Bio & Medical
Technology Development Program of the Ministry of Educa-
tion, Science, and Technology, Korea (http://www.kgcb.or.
kr). All tumor tissues were histologically reviewed and only
specimens with a sufficient abundance of tumor cells were
included in tissue microarray construction. Staging was
performed according to the International Federation of
Gynecology and Obstetrics (FIGO) staging system. Primary
treatment for invasive cervical cancer consisted of a type 3
radical hysterectomy with pelvic lymph node dissection.
Concurrent Platinum-based chemoradiation was given in cases
with increased risk of recurrence, such as positive resection
margins, positive lymph nodes, or parametrial invasion.
Medical records were reviewed to obtain data including age,
surgical procedure, survival time, and survival status. Response
to therapy was assessed according to the Response Evaluation
Criteria in Solid Tumors (RECIST; version 1.0), either by
computed tomography or magnetic resonance imaging [11].
Data on tumor size, cell type, tumor grade, and lymph node
metastasis were obtained by reviewing pathology reports. The
study protocol was approved by the Institutional Review
Boards (IRBs) of Gangnam Severance Hospital and the Office
of Human Subjects Research at the National Institutes of
Health (NIH).
Construct of SCP3 and its deletion mutant expression
vectors
hSCP3 full and deletion mutants were created with a PCR-
based strategy from a human testis cDNA library (Clontech,
Moutain View, CA) with the following primers: hSCP3 1 forward
59-GCTCGAGATGGTGTCCTCCGGAAAAAAG-39; hSCP3
81 forward 59-CCCTCGAGACCATGATTAACAAGGCTC-
TTCTT-39; hSCP3 131 forward 59-GGCTCGAGATGGATA-
TGCAGAAAGCTGAG-39; hSCP3 80 reverse 59-CGAATTCT-
CAGTCAACTCCAACTCCTTCCA-39; hSCP3 130 reverse 59-
CGAATTCTCAGAAACTGCTGAGAATAT-39; hSCP3 236
reverse 59-CGAATTCAGTCTTATTGTACCTAACTTCTCT-
G-39. hSCP3 1-236 (full), 1-80, 1-130, 81-236, and 131-236
fragments were subcloned into the pMSCV-puro vector (Clon-
tech) at the Xho I and EcoR I restriction sites. Recombinant
pMSCVs encoding SCP3 or its deletion mutants were confirmed
by DNA sequence analysis.
Construct of shSCP3 vectors
To generate the Scp3 short hairpin RNA (shRNA) exoression
construct human Scp3-shRNA annealed forward 59 GATCCG-
GAGAAGAATCATGATAATTCAAGAGAT TATCATGATT-
CTTCTCCTTTTTTGGAAA-39 (BamHI-compatible) and reverse
59- AGCTTTTCCAAAAAAGGAGAAGAATCATGATAATC-
TCTTGAATTATCATGATTCTTCTCCG-39 (HindIII-compati-
ble) oligonucleotides were ligated to BamHI/HindIII-digested
pSilencer 3.1-H1 puro. The shRNA control employed for these
studies was a scrambled DNA sequence that does not target any
identified human coding sequence (Ambion, Austin, TX).
Western blot analysis
For each experiment, a total of 56105 cells were rinsed twice
with ice-cold PBS and added 0.2 mL of the Protein Extraction
Solution RIPA (Elpis Biotech, Daejeon, Korea) [50 mM Tris Cl,
pH 8.0, 150 mM NaCl, 1 mM phenylmethylsulphonyl fluoride
(PMSF), 0.1% sodium dodecyl sulphate (SDS), 1% Nonidet P-40
(NP-40), 0.5 mM EDTA], incubated for 30 min on ice, and then
were scraped and centrifuged. Protein concentrations were
determined by the coomassie plus protein assay (Pierce, Rockford,
USA). 50 mg of protein were solubilized in Laemmli buffer
(62.5 mM Tris/HCL pH 6.8, 10% glycerol, 2% SDS, 5%
mercaptoethanol and 0.00625% bromophenol blue), boiled for
5 min, and then separated by SDS polyacrylamide gel electro-
phoresis. Separated gel was transferred to nitrocellulose mem-
branes at 90 V for 1 hr on ice. Primary antibodies against
phospho AKT (Ser473), AKT, and phospho ERK (T202/Y204)
were purchased from Cell Signaling (Beverly, MA) and used at a
dilution of 1:1000. Likewise, primary antibodies against dual
phospho p38 MAPK (Stressgen, Victoria, Canada) and SCP3 (BD
Biosciences, San Jose, CA) were used at a dilution of 1:1000, while
antibodies against b-actin and Flag (Sigma-Aldrich, St. Louis,
MO) were used at a dilution of 1:10,000 in Tris-buffered saline
(TBS)-T containing 5% BSA (Santa Cruz Biotechnology, Santa
Cruz, CA) at 4uC overnight, followed by 3 washes in TBST, 5
minutes per wash. Goat anti-mouse IgG-HRP, anti-rabbit IgG-
HRP secondary antibodies (1:5000) (Stressgen) were incubated for
1 hr at room temperature conjugated with horseradish peroxidase.
Immunoreactive bands were visualized by enhanced chemilumi-
nescence (ECL, Elpis Biotech). Densitometry was performed using
an image analyzer Fujifilm LAS-4000 (Fuji, Tokyo, Japan) and
Multi Gauge V3.1 imaging software (Fujifilm Medical systems
USA, Inc., Edison, NJ). To quantitate the intensity profile of
protein band images, we used Image J densitometry software
SCP3 in Cervical Cancer
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(Version 1.6, National Institutes of Health, Bethesda, MD). The
band images were scanned in grayscale at a resolution of at least
600dpi and expressed a percentage of the total size of all the
measured peaks. To calculate a relative value, the intensity of each
sample was divided by that of control. Numbers below western
blots refer to the relative values of the intensity normalized to each
control.
Cell proliferation and colony formation assays
For cell proliferation assays, the cells (n = 3) were grown in six
well plates at a density of 16104 cells per well for 3 days. The
percentages of live cells were determined using a hematocytometer
after 0.4% trypan blue staining. Measurements were made in
triplicate for each of the cell lines and the experiments were
repeated three times. For the soft-agar colony formation assay,
16104 NIH3T3 cells, CaSki cells and HeLa cells were plated in 6-
well culture plate as a suspension in 2 mL of DMEM containing
10% FBS and 0.4% agar on top of the base layer of 0.7% agar
containing 2 mL of the same medium. Plates were incubated at
37uC for 2 weeks until colonies were formed. Two weeks later, .
2 mm colonies were counted with an ocular micrometer on a
microscope. All experiments repeated at least twice.
siRNA treatment
Synthetic small interfering RNA (siRNA) specific for green
fluorescent protein (GFP) and mouse AKT were purchased from
Invitrogen (Carlsbad, CA). The following sequences were used:
GFP (non-specific target control) 59-GCAUCAAGGUGAACUU-
CAA-39 (sense), 59-UUGAAGUUCACCUUGAUGC-39 (anti-
sense); AKT, 59-GACAACCGCCAUCCAGACU-39 (sense), 59-
AGUCUGGAUGGCGGUUGUC-39 (antisense). For in vitro
delivery, NIH3T3 cells on a 6-well vessel were transfected with
300 pmol of the synthesized siRNAs using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. The
siRNA-treated cells were collected 48 h after transfection for
western blot analysis, cell proliferation assay, and colony forming
assay.
Tumor formation
The transfected NIH3T3 cells (16105 cells/mouse), CaSki cells
(16106 cells/mouse), or HeLa cells (16106 cells/mouse) were
injected subcutaneously into Balb/c Nude mice. Tumor size was
measured twice a week for 24 days after tumor cell injection. Each
individual tumor size was measured with a caliper, and the tumor
volume was calculated using the following formula: tumor volume
(mm3) = [width6length2]/2 [12].
Immunofluorescent labeling of tumor tissue sections
Tumor tissue samples were fixed and embedded in Tissue-Tek
O.C.T. compound (Sakura Finetechnical, Tokyo, Japan) in molds.
For immunofluorescent analyses, 10-mm cryosections were placed
on poly-L-lysine–coated slides, fixed in 4% paraformaldehyde, and
blocked in PBS with 10% normal goat serum (NGS) (NGS/PBS).
Tissue sections were incubated with pAKT antibody (1:100; Cell
signaling) for overnight at 4uC. After washing, sections were
incubated with the secondary Alexa555-conjugated goat anti–
rabbit IgG (1:1000 in NGS/PBS; Molecular Probes, Eugene, OR)
and then mounted in Fluorescent Mounting medium (Dako,
Glostrup, Denmark) on glass microscope slides. All images were
acquired using a Zeiss LSM 5 Pascal confocal microscope (Carl
Zeiss, Jena, Germany). To quantitate the intensity profile of pAKT
fluorescence image in tumor tissue sections, we used ImageJ
densitometry software. The tumor tissues on slides were scanned in
grayscale at a resolution of at least 600dpi. Tumor areas on
scanned images were selected more than 10 times from each group
with freehand tool and measured the mean grey value. To
calculate a relative value, the intensity of each sample was divided
by that of blank slides (without primary antibody).
Tissue microarray construction
Full-face sections of all donor blocks were stained with
haematoxylin and eosin (H&E) and reviewed by a pathologist
who marked representative tumor areas. The tissue microarray
(TMA) was constructed using a Manual Tissue Arrayer MTA-1
(Beecher Instruments Inc., Silver Spring, MD). Four 1.0 mm
diameter tissue cores consisting of matched tumor specimens
and normal epithelial samples were extracted from selected
regions of each donor block. The presence of tumor tissues on
the TMA was verified with H&E staining. Multiple 5 mm thick
sections were cut with a microtome and H&E staining of TMA
slides were examined every 50th section for the presence of
tumor cells.
Immunohistochemistry and scoring
TMA sections were deparaffinized and hydrated in xylene
and descending gradient alcohol solutions. Endogenous per-
oxidase was blocked by incubation in 3% H2O2 for 10 minutes.
Antigen retrieval was performed in a steam pressure cooker
(Pascal, Dako, Carpinteria, CA) with prewarmed antigen
retrieval buffer pH 9 (Dako) at 95uC for 10 minutes. To
minimize nonspecific staining, sections were incubated with
protein block (Dako) for 20 minutes. The sections were
incubated with an anti-SCP3 antibody (clone 25/SCP3, BD
Biosciences, dilution 1:500) overnight at 4uC or an anti-pAKT
antibody (Cell Signaling; dilution 1:200) for 120 minutes at
room temperature. EnVision FLEX+ and EnVision+ Dual
Link System (Dako) were used for the detection of SCP3 and
pAKT, respectively. Staining was visualized using 3,39-
Diaminobenzidine (DAB) and the sections were counterstained
with hematoxylin. Finally, the slides were covered and
observed under a light microscope (Axioplot, Carl Zeiss, Jena,
Germany). In this study, five conventional whole section slides
were carefully selected to validate the immunohistochemical
staining performed for SCP3 and pAKT. During this process,
staining patterns were thoroughly compared, and some of the
patterns matched those of conventional slides from the same
case. Furthermore, in designing this study, stromal cells from
the whole sections of cercival cancer were selected as internal
positive control while the primary antibody was omitted from
the negative control.
SCP3 and pAKT staining results were scored based on (a)
intensity [categorized as 0 (absent), 1 (weak), 2 (moderate), or 3
(strong)] and (b) the percentage of positive stained epithelial
cells [scored as 0 (0% positive), 1 (1–25%), 2 (26–50%), 3 (51–
75%), or 4 (.75%)] (Figure S1). An overall protein expression
score was calculated by multiplying the intensity and positivity
scores (overall score range, 0–12). The IHC score was then
dichotomized into high expression (SCP3 IHC score of .7 and
pAKT score of .7, respectively), and low expression (IHC
score of #7 in both SCP3 and pAKT). Receiver operating
characteristic (ROC) analysis was used when determining the
cut-off values of the SCP3 and pAKT. The sensitivity and
specificity for discriminating death or alive was plotted at each
IHC score and cut-off value was established to be the point of
the ROC curve where the sum of sensitivity and specificity was
maximize [13]. Two independent pathologists with experience
SCP3 in Cervical Cancer
PLOS ONE | www.plosone.org 3 June 2014 | Volume 9 | Issue 6 | e98712
in tissue microarray analysis examined the slides without any
knowledge of the corresponding clinical data.
Statistical analysis
All data are representative of at least 2 independent experi-
ments. Non-parametric 1-way or 2-way ANOVA was performed
with SPSS version 18.0 software (SPSS Inc., Chicago, IL).
Comparisons between individual data points were assessed with
Student’s T-test. Statistical analyses of SCP3 and pAKT
expression were performed using the Mann-Whitney test and
the Kruskal-Wallis test. The Spearman nonparametric correlation
test was used to analyze the relationship between SCP3 and
pAKT. Survival curves were estimated by Kaplan-Meier analysis.
The log-rank test was used to compare the differences of survival
distribution between groups. The multivariate analysis with Cox
proportional hazards model was performed to identify indepen-
dent predictors of disease-free survival in adjustment with relevant
clinical covariates such as age, FIGO stage, histologic type, tumor
grade, tumor size, and lymph node status. The final model was
chosen based on the result of univariable analysis as well as
consideration of the clinical or biological importance of the
variables. All statistical tests were two-sided, and P values,0.05
were considered statistically significant.
Results
Ectopic expression of hSCP3 increases proliferation and
tumorigenicity of NIH3T3 cells
A previous study reported that human SCP3 (hSCP3) is
expressed in various cancer cells and that its expression in human
specimens is associated with oncogenesis [8,10]. However, the
oncogenic potential of SCP3 has not been sufficiently character-
ized at either the molecular or cellular level. To examine whether
hSCP3 may have cellular tumorigenic potential, we first used a
non-tumorigenic murine fibroblast NIH3T3 cell line and estab-
lished the cell lines expressing hSCP3 using a retroviral
transduction system (NIH3T3/hSCP3). NIH3T3/no insert (emp-
ty vector) cells were also established as a control. The expression of
SCP3 protein in NIH3T3/hSCP3 cells was confirmed by Western
blot (Figure 1A). Cell proliferation of transduced NIH3T3 cells
was measured by counting the number of live cells after trypan
blue staining. In cell proliferation assays (Figure 1B), NIH3T3/
hSCP3 cells exhibited a significantly increased proliferation rate
compared with NIH3T3/no insert cells (P,0.005). The results of
a soft agar colony formation assay with the same cell lines were
consistent with those of the cell proliferation assay (Figure 1C).
NIH3T3/hSCP3 cells exhibited significantly higher potentials of
colony formation in soft agar as compared with NIH3T3/no insert
cells (P,0.005). We next subcutaneously injected hSCP3- or no
Figure 1. hSCP3 increases oncogenic potentials of NIH3T3 cells in vitro and in vivo. (A) Western blot analysis of expression of hSCP3 in
NIH3T3 cells retrovirally transduced with a pMSCV vector encoding hSCP3 (NIH3T3/hSCP3). NIH3T3/No insert cells were used as a control. Numbers
below western blots refer to the relative values of the intensity normalized to no insert control. (B) In vitro growth curves of NIH3T3/hSCP3 cells. Cells
were counted after trypan blue staining to exclude dead cells. (C) Colony-forming capacity of NIH3T3/hSPC3 cells in soft agar; (left) Representative
images of average colony size in each group; (right) Bar graph representing the number of colonies with diameters greater than 2 mm in soft agar
(scale bar: 1 mm). (D) Tumorigenicity of NIH3T3/hSCP3 cells. Balb/c Nude mice (n = 5) were inoculated subcutaneously with 16105 cells/mouse of
NIH3T3/no insert or NIH3T3/hSCP3 cells. Error bars represent the mean 6 SD.
doi:10.1371/journal.pone.0098712.g001
SCP3 in Cervical Cancer
PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e98712
insert-expressing NIH3T3 cell in the left flank of athymic Balb/c
Nude mice (Figure 1D). Consistent with our in vitro data, the
tumor-forming ability of NIH3T3 cells was drastically increased by
ectopically-expressing hSCP3 (no insert vs. hSCP3, P,0.001). We
next explored whether other genes from the murine Cor1 family
such mXLR, mXMR and mSCP3, which share more than 60%
homology with hSCP3, could have similar tumorigenic potential
in the NIH3T3 model [10]. As shown in Figure S2, ectopic
expression of Cor1 family members substantially promoted in vitro
cell proliferation and soft agar colony formation as well as in vivo
tumor formation in NIH3T3 cell line model, which was consistent
with that of the hSCP3. Taken together, these data clearly
demonstrate the oncogenic potentials of SCP3 and other Cor1
members in NIH3T3 model.
hSCP3 promotes tumorigenesis through AKT pathway in
NIH3T3 cells
We previously reported that pAKT level is increased in hSCP3-
expressing cervical cell lines [10]. To evaluate changes in various
signaling molecules that may play a role in the global control of
cell proliferation, we performed Western blot analysis to measure
the levels of Ser 473 phosphorylated AKT, Thr 202/Tyr 204
phosphorylated ERK, and Thr 180/Tyr 182 phosphorylated p38
MAP kinase in NIH3T3 cells expressing hSCP3 or no insert
(empty vector). We observed that the expression of pAKT was
significantly increased in cells transduced with hSCP3 compared
to control cells (Figure 2A). Next, to explore the relationship
between hSCP3-mediated tumorigenic potential and the AKT
signaling, we compared both cell proliferation and soft agar colony
forming capability of NIH3T3/hSCP3 cells in the presence of
control (DMSO), 10 mM API2 (an inhibitor of AKT), 50 mM
PD98059 (an inhibitor of MEK/ERK) or 10 mM SB203580 (an
inhibitor of p38-MAPK) (Figure 2B and 2C). Treatment with PD
98059 and SB203580 did not significantly affect the proliferation
and the colony formation capacity of NIH3T3/hSCP3 cells
compared with that of DMSO. On the contrary, API2 treated
NIH3T3/hSCP3 cells exhibited a significantly decreased prolifer-
ation rate compared with DMSO-treated control (P,0.001).
Consistently, API2-treated NIH3T3/hSCP3 cells also formed
smaller colonies, the number of which was almost 5-times less than
colonies formed by DMSO-treated NIH3T3/hSCP3 cells. Thus,
it is obvious that both proliferation and colony formation in these
cells are dependent on the AKT signaling. To exclude potential
off-target effects of API2, we performed in vitro cell proliferation
and soft agar colony formation experiments using siRNA-targeting
Figure 2. hSCP3 increases tumorigenesis through AKT pathway. (A) Western blot analysis of levels of pAKT, pERK, and pp38 in NIH3T3 cells
ectopically expressing hSCP3 or no insert. Numbers below western blots refer to the relative values of the intensity normalized to no insert control.
(B) In vitro growth curves of NIH3T3/hSCP3 cells treated with DMSO or API2 (Akt inhibitor), PD98059 (Erk inhibitor), or SB203580 (p38 inhibitor). (C)
Soft agar colony-forming capacity of NIH3T3/hSPC3 cells in the presence of API2, PD98059, or SB203580; (C, Right) Representative images of average
colony size in each group; (C, Left) bar graph showing the number of colonies with diameters greater than 2 mm in soft agar (scale bar: 1 mm). (D)
Western blot analysis of levels of pAKT in NIH3T3/hSCP3 cells transfected with a siRNA targeting GFP or AKT (siGFP or siAKT) to confirm the reduction
of AKT protein level. Numbers below western blots refer to the relative values of the intensity normalized to no insert control. (E) In vitro growth
curves of NIH3T3/hSCP3 cells transfected with siGFP or siAKT. (F) Soft agar colony-forming capacity of NIH3T3/hSPC3 cells treated with siGFP or siAKT;
(Left) Representative images of average colony size in each group; (Right) Bar graph representing the number of colonies with diameters greater than
2 mm in soft agar (scale bar: 1 mm). Error bars represent the mean 6 SD.
doi:10.1371/journal.pone.0098712.g002
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AKT (siAKT) to block the AKT pathway. siRNA targeting to
irrelevant GFP (GFP siRNA) was used as a negative control.
Consistent with API2 data, siAKT-treated NIH3T3/hSCP3 cells
exhibited a decreased rate of cell proliferation (Figure 2D and 2E)
and colony number compared with control siGFP-treated
NIH3T3/hSCP3 cells (Figure 2F). Similar AKT dependency
was also observed in NIH3T3 cells expressing mXLR, which
displayed the most potent tumorigenic potential among members
of the murine Cor1 family (Figure S3). Thus, our data demonstrate
that SCP3 and the other Cor1 members could confer tumorigenic
potentials upon NIH3T3 cell through AKT pathway.
The C-terminal region of hSCP3 is sufficient to increase
pAKT levels and enhance tumorigenesis
As schematized in Figure 3A, hSCP3 contains a nuclear
localization signal (NLS, residues 88–91), Gln-rich (residues
106–139) and coiled-coil (residues 131–236) motifs. To identify
key motifs involved in hSCP3-mediated oncogenesis, we con-
structed four deletion mutants of hSCP3 containing different
motifs (Figure 3A). The N-termini of full hSCP3 and the deletion
mutants were tagged with a Flag epitope for visualization by
Western blot. We then characterized the expression and the
function of hSCP3 and its mutants in retrovirus-transduced
NIH3T3 cells. Notably, mutants lacking the coiled-coil motif
(hSCP31-80 and hSCP31-130) failed to increase phosphorylation of
Figure 3. The C-terminal region of hSCP3 is important for its oncogenic capability. (A) Schematic of the domains in hSCP3. Boxes
represent the NLS, Gln-rich, and coiled-coil motifs, respectively. (B) Western blot analysis of levels of hSCP3 and its deletion mutants, the N-termini of
which were tagged with a Flag epitope for visualization. Numbers below western blots refer to the relative values of the intensity normalized to no
insert control. (C) Soft agar colony-forming capacity of NIH3T3 expressing wild type or deletion mutants of hSCP3. (D) In vitro growth curves of
NIH3T3 cells expressing wild type or deletion mutants of hSCP3. Cells were counted after trypan blue staining to exclude dead cells. (E) In vivo
tumorigenicity of the NIH3T3 cells. Balb/c Nude mice (n = 5) were inoculated subcutaneously with 16105 cells/mouse of the NIH3T3 cells expressing
full length or mutant hSPC3. Error bars represent the mean 6 SD. (F) Representative images of skin tumors (scale bar: 60 mm). (G) Bar graph
representing intensity of pAKT fluorescence image on tumor tissue sections, ImageJ densitometry software was used to quantitate the intensity of
image as described in Materials and Methods. Error bars represent the mean 6 SD.
doi:10.1371/journal.pone.0098712.g003
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AKT (Figure 3B). Conversely, hSCP381-236 and hSCP3131-236
mutants containing the coiled-coil motif successfully increased
levels of pAKT (Figure 3B). Consistent with these observations,
NIH3T cells expressing hSCP381-236 or hSCP3131-236 exhibited an
increased rate of cell proliferation and number of colony
compared with those expressing hSCP31-80 and hSCP31-130 as
well as no insert (Figure 3C and 3D). More importantly, as shown
in Figure 3E-3G, similar phenomena were also observed in vivo
with tumor xenograft experiments. The tumor-forming ability of
NIH3T3 cells was drastically increased after ectopic expression of
hSCP381-236 and hSCP3131-236 [no insert vs. hSCP381-236 (P,0.01)
or hSCP3131-236 (P,0.003)]. Similarly, immunofluorescence
staining for pAKT was increased substantially in histological
sections of tumors ectopically expressing hSCP381-236 or
hSCP3131-236 [no insert vs. hSCP381-236 (P,0.05) or hSCP3131-
236 (P,0.003)] (Figure 3G). Taken together, our data indicate that
the coiled-coil motif containing the C-terminal region is the
primary contributor to the AKT-dependent oncogenic potential of
hSCP3.
SCP3 has a key role in proliferation and tumorigenicity of
cervical cancer cells
We further investigated the oncogenic role of SCP3 and its
relationship with phosphorylated AKT (pAKT) in human cervical
cancer cell lines. For this, the expression of SCP3 was measured in
human cervical cancer cell lines CUMC6, SiHa, CaSki, and HeLa
using western blot analysis. As shown in Figure 4A, expression of
SCP3 was observed in all of cervical cancer cells although that of
SCP3 was most profound in HeLa cells. In contrast, CaSki cells
exhibited lowest expression of SCP3 protein. Next, to evaluate the
effects of SCP3 on cell proliferation and tumorigenicity in cervical
cancer cells, we established the CaSki cell lines expressing hSCP3
or no insert (empty vector) using a retroviral transduction system
CaSki/hSCP3 or CaSki/no insert, respectively. Conversely, we
Figure 4. hSCP3 increases oncogenic potentials of human cervical cancer cells in vitro and in vivo. (A) Western blot analysis of levels of
SCP3 in human cervical cancer cell lines CUMC6, SiHa, CaSki, and HeLa cells. Numbers below western blots refer to the relative values of the intensity
normalized to CUMC6 control. (B) Western blot analysis of expression of SCP3, pAKT, and AKT in CaSki cells retrovirally transduced with a pMSCV
vector encoding hSCP3 (CaSki/hSCP3). CaSki/no insert cells were used as a control. Numbers below western blots refer to the relative values of the
intensity normalized to no insert control. (C) In vitro growth curves of CaSki/hSCP3 cells. Cells were counted after trypan blue staining to exclude dead
cells. (D) Colony-forming capacity of CaSki/hSCP3 cells in soft agar; (Top) Representative colony images of each group; (Bottom) Bar graph
representing the number of colonies with diameters greater than 2 mm in soft agar (scale bar: 1 mm). (E) Tumorigenicity of CaSki/hSCP3 cells. Balb/c
Nude mice (n = 5) were inoculated with CaSki/no insert or CaSki/hSCP3 cells (16106 cells/mouse) subcutaneously. (F) Western blot analysis of
expression of SCP3, pAKT, AKT in HeLa/shSCP3 cells. HeLa/shGFP were used as a control. Numbers below western blots refer to the relative values of
the intensity normalized to shGFP control. (G) In vitro growth curves of HeLa/shSCP3 cells. (H) Colony-forming capacity of HeLa/hSCP3 cells in soft
agar (scale bar: 1 mm). (I) Tumorigenicity of HeLa/shSCP3 cells. Balb/c Nude mice (n = 5) were inoculated subcutaneously with 16106 cells/mouse of
HeLa/shGFP or HeLa/shSCP3 cells. Error bars represent the mean 6 SD.
doi:10.1371/journal.pone.0098712.g004
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established the HeLa cell lines expressing shRNA targeting SCP3
(shSCP3) or GFP (irrelevant negative control, shGFP) using a
shRNA expressing vector (pSilencer 3.1-H1 puro), HeLa/shSCP3
or HeLa/shGFP, respectively, after puromycin selection. First of
all, SCP3, pAKT, AKT protein levels in the CaSki cells were
measured by western blotting. As shown in Figure 4B, the
expression of pAKT was significantly increased in CaSki/SCP3
cells compared with control CaSki/no insert cells. The cell growth
assay revealed that cell growth rate in the SCP3-transduced cells
was significantly higher than control cells (Figure 4C). Similar
increase was also observed in colony formation assay (Figure 4D).
Consistent with in vitro data, the tumor-forming ability of CaSki
cells was significantly increased after introducing SCP3 (Figure 4E).
In contrast, knock-down of SCP3 in HeLa cells significantly
decreased pAKT level, in vitro cell growth rate and colony
formation efficacies and in vivo tumor growth rate compared with
shGFP control group (Figure 4F–4I). These data demonstrate that
SCP3 has a key role in cell proliferation and tumorigenicity of
cervical cancer cells.
SCP3 and pAKT are overexpressed in tumor samples from
patients with cervical cancer
Having elucidated the molecular mechanism by which SCP3
activation promotes tumor growth via the AKT pathway, we next
examined SCP3 and pAKT protein expression levels by immu-
nohistochemistry in cervical tissue specimens from patients with
CIN or invasive cervical cancer. Table S1 summarizes patient’s
clinicopathological characteristics. In 181 patients with cervical
cancer, 118 patients of stage I, 54 of stage II and 9 of stage IV
were included. The ages of the patients ranged from 19 to 83 years
(mean, 42.4 years). The tumor sizes ranged from 0.2 to 12 cm
(mean, 2.9 cm).
Representative immunohistochemical staining of SCP3 and
pAKT are shown in Figure 5A. Immunohistochemical staining of
SCP3 was observed in the cytoplasm of tumor cells as previously
reported in non-small cell lung cancer [8]. The TMA constructed
in this study consisted of 181 cases of cervical cancer, however due
to the complexity of sectioning, staining, as well as heterogeneity of
the samples, 176 (97.2%, SCP3) and 178 (98.3%, pAKT) of which
were suitable for IHC evaluation. Detailed IHC scoring patterns
are shown in Table S2. A total of 108 of 176 cancers (61.4%) had
high expression (cut-off value: 7) of SCP3 whereas 100 of 178
cancers (56.2%) had elevated expression (cut-off value: 7) of
pAKT. The level of SCP3 and pAKT expression increased as
tumor state progressed from low-grade CIN to high-grade CIN to
cancer (Figure 5A and 5B; Table S2). Moreover, SCP3 expression
was significantly correlated with FIGO stage (P=0.002), differen-
tiation (P,0.001) and chemoradiation response (P=0.005).
Figure 5. SCP3 overexpression is associated with tumor progression in human cervical neoplasia specimens. (A) Representative
immunohistochemical staining images of SCP3 and pAKT in cervical tissue from patients with low-grade CIN, High-grade CIN, and cervical carcinoma.
Boxed regions are displayed at high magnification in insets (scale bar: 300 mm). (B) Box plot depiction of IHC staining scores. There was an increasing
amount of SCP3 and pAKT expression as tumor stage progressed from low-grade CIN to high-grade CIN to cancer. Symbols indicate individual
samples. Numbers associated with symbols indicate case numbers.
doi:10.1371/journal.pone.0098712.g005
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However, there was no statistically significant difference between
pAKT expression and clinicopathologic factors.
We next examined the association between SCP3 and pAKT
expression. Of the 400 CIN specimens, 344 (86.0%) were available
to confirm co-expression between SCP3 and pAKT, whereas 173
tumor samples (95.6%) were available to confirm co-expression
between SCP3 and pAKT in cervical cancer. Notably, expression
of SCP3 showed a positive linear correlation with that of pAKT
both in CIN (Spearman’s rho= 0.322, P,0.001) and cervical
cancer (Spearman’s rho= 0.221, P=0.010) (Table 1, Figure
S4).Taken together, these results suggest that SCP3 expression
may be involved in the development of cervical cancer develop-
ment and linked with the AKT signaling pathway.
SCP3 overexpression is correlated with poor prognosis of
patients with cervical cancer
To investigate the clinical relevance of SCP3, we examined the
effect of SCP3 expression on patient outcomes. Five-year disease-
free survival and overall survival were analyzed through Kaplan-
Meier plots as shown in Figure 6A and B. In survival analysis of
SCP3, there were 33 cases of recurrences, 2 cases of persistent
disease, and 18 deaths in the 108 patients with high expression of
SCP3, whereas low expression of SCP3 (68 patients) was
associated with 4 cases of recurrence and 2 deaths over a mean
follow-up period of 56.32 months. Patients with high SCP3
expression displayed shorter disease-free survival (mean of 122.4
versus 153.5 months, P=0.001) and overall survival (mean of
144.8 versus 159.6 months, P=0.024) compared with that of
patients with low expression of SCP3 (Figure 6A and 6B).
Furthermore, patients with combined high SCP3 and high pAKT
exhibited significantly worse disease-free survival (mean of 106.7
versus 160.3 months, P,0.001) and overall survival (P=0.009)
compared with the combined low SCP3 and low pAKT group.
Interestingly, there were no deaths in combined low SCP3 and low
pAKT patients (n = 37). We next examined the independent
prognostic significance of SCP3 alone and high SCP3 combined
with high pAKT, as well as other clinicopathological parameters,
using the Cox proportional hazards model. According to
multivariate analysis, FIGO stage was a significant risk factor for
overall survival (P=0.013), whereas lymph node metastasis
remained a significant risk factor for disease-free survival
(P=0.024) (Table 2). High SCP3 expression was a risk factor for
recurrence [hazard ratio = 5.52 (95% CI, 1.78–17.11), P=0.003],
whereas high pAKT expression was a risk factor for disease-free
survival [hazard ratio = 3.62 (95% CI, 1.19–11.05), P=0.023] and
overall survival [hazard ratio = 3.60 (95% CI, 1.04–12.42),
P=0.043]. Notably, the combination of high SCP3 and high
pAKT expression was a significant risk factor for both disease free
survival [hazard ratio = 4.98 (95% CI, 1.90–13.01), P=0.001] and
overall survival [hazard ratio = 3.38 (95% CI, 1.21–9.43),
P=0.020].
Discussion
There is increasing evidence that hSPC3 may play a role in
oncogenesis; however, the evidence has not been addressed at a
cellular or molecular level. In this report, we provide the first
compelling data that hSCP3 can play a key role in human
tumorigenesis. We demonstrate that ectopic expression of hSCP3
in conventional non-tumorigenic murine NIH3T3 cells and a
human cervical cancer cell line CaSki cells leads to increased cell
proliferation and colony formation in vitro as well as increased
tumor growth in vivo using a mouse model system. Furthermore,
we observed activation of the AKT pathway in hSCP3-overex-
pressing cells. Interestingly, AKT activation appeared to be
associated with hSCP3-mediated oncogenic potential, which was
confirmed using an API-2 chemical inhibitor, siAKT treatment,
and deletion mutant analysis.
The AKT pathway plays a pivotal role in transformation by
inducing cell survival, growth, migration, and angiogenesis [13–
17]._ENREF_13 Recently, we reported that increased activation
of AKT is associated with multiple resistance of tumor cells to
various cancer drugs, radiation, as well as cytotoxic T lymphocyte
(CTL)-mediated cell death [18–21]. In this paper, we demonstrat-
ed that hSCP3-mediated oncogenic potentials were primarily
mediated by an AKT-dependent pathway. Likewise, it was not
surprising that similar AKT dependency was present for murine
Cor1 members as demonstrated in Figure S1 and S2, because they
share more than 60% homology with hSCP3 [10]. However, we
don’t exclude the possibility of AKT-independent mechanism in
SCP3-mediated oncogenesis since its hSCP31-80 deletion mutant
exhibited a significant increase of colony number, proliferation,
and tumor volume despite the lack of increased Akt phosphory-
lation in a NIH 3T3 tumor cell model as shown in Figure 3.
Further studies are needed to demonstrate the direct relationship
between SCP3 expression and activation of AKT in cervical
cancer.
SCP3 is well known as a nuclear protein in meiotic germ cells
[22], whereas altered subcellular localization of SCP3 has been
reported in various cancer cells as well as human lung cancer tissue
specimens [8]. Furthermore, in a previous pilot study using a
limited number of cervical cancer specimens, we observed
Table 1. Association between SCP3 and pAKT expression in CIN and cervical cancer.
SCP3 expression
Low % High % Total No. Correlation coefficient (r) p value
pAKT expression
CIN 0.322 ,0.001
Low 233 90.7 24 9.3 257
High 62 71.3 25 28.7 87
Cervical cancer 0.221 0.010
Low 38 50.0 38 50.0 76
High 29 29.9 68 70.1 97
CIN, cervical intraepithelial neoplasia.
doi:10.1371/journal.pone.0098712.t001
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cytoplasmic localization of SCP3 by IHC [10]. The ectopic
expression of tumor suppressor proteins can disrupt normal cell
differentiation programs and accelerate cancer progression.
Therefore, our findings suggest that the cytoplasmic expression
of SCP3 may be a cancer-specific phenomenon linked to cancer
progression by an unknown mechanism. In the current study, we
Figure 6. Kaplan-Meier plots for disease-free survival (A) and overall survival (B) according to SCP3 expression, combined SCP3
and pAKT expression, and pAKT expression alone. For patients with high SCP3 expression, the mean disease-free survival and overall survival
were 122.4 months and 144.8 months (n = 108), respectively. For patients with low SCP3 expression, mean disease-free survival and overall survival
were 153.5 months and 159.6 months (n = 68), respectively.
doi:10.1371/journal.pone.0098712.g006
Table 2. Univariate and multivariate analyses of the associations between prognostic variables and disease-free survival or overall
survival in cervical cancer.
Disease-free Survival hazard ratio [95% CI], P value Overall Survival hazard ratio [95% CI], P value
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Age 0.99 [0.97–1.02], 0.923 NA 0.98 [0.94–1.03], 0.583 NA
FIGO stage 5.32 [2.76–10.24], ,0.001 1.88 [0.79–4.46], 0.153 3.27 [1.32–8.07], 0.010 3.26 [1.28–8.31], 0.013
Cell type (non-SCC) 1.15 [0.50–2.63], 0.732 NA 2.68 [1.06–6.76], 0.035 2.72 [1.06–6.98], 0.037
Tumor grade (poor) 1.98 [1.03–3.81], 0.040 1.64 [0.76–3.53], 0.207 2.40 [0.96–5.97], 0.060 NA
Tumor size (.4 cm) 2.43 [1.27–4.65], 0.007 1.93 [0.84–4.40], 0.117 1.83 [0.74–4.54], 0.188 NA
LN metastasis 4.97 [2.38–10.38], ,0.001 2.57 [1.13–5.87], 0.024 2.23 [0.76–6.47], 0.141 NA
SCC Ag+ 1.45 [0.71–2.96], 0.307 NA 1.80 [0.69–4.68], 0.225 NA
SCP3+ 5.14 [1.82–14.52], 0.002 5.52 [1.78–17.11], 0.003 4.63 [1.07–20.01], 0.040 3.50 [0.79–15.44], 0.097
pAKT+ 4.89 [1.90–12.58], 0.001 3.62 [1.19–11.05], 0.023 4.34 [1.27–14.86], 0.019 3.60 [1.04–12.42], 0.043
SCP3+/pAKT+ 4.97 [2.34–10.53], ,0.001 4.98 [1.90–13.01], 0.001 4.16 [1.51–11.46], 0.006 3.38 [1.21–9.43], 0.020
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; SCC, squamous cell carcinoma; LN, lymph node; NA, not applicable.
doi:10.1371/journal.pone.0098712.t002
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confirmed that the percentage of patients expressing SCP3 in
cervical cancer was relatively high (61.4% of all cases), and was
significantly associated with the progression of cervical carcino-
genesis from low-grade CIN to high-grade CIN to cancer (Table
S1, P,0.001). To the best of our knowledge, this is the first report
to show that SCP3 protein expression increases according to
severity of cervical lesions. Moreover, we observed that SCP3
protein expression was significantly associated with advanced
tumor stage (P=0.002), poor tumor grade (P,0.001), and poor
response to chemoradiation therapy (P=0.005), and exhibited the
highest levels of expression in metastatic tissue specimens (Table
S1). Notably, consistent with our previous report in non-small cell
lung cancer [8], high SCP3 expression in cervical cancer conferred
a significantly shorter survival time, suggesting that it may be a
potential prognostic predictor for cervical cancer. Based on Cox
multivariate analysis, SCP3+, pAKT+, SCP3+/pAKT+, and
lymph node metastasis was associated with increased risk of
recurrence of cervical cancer. Moreover, SCP3+/pAKT+ was the
only independent prognostic factor for both disease-free and
overall survival according to multivariate analysis (Table 2). Taken
together, these results strongly implicate SCP3 as an important
aspect in the pathogenesis of cervical cancer. Likewise, evaluation
of SCP3 expression in cervical cancer may be useful for prediction
of chemoradiation response, stratified prognosis, and determining
follow-up strategies.
Lastly, we examined the correlation of SCP3 expression with
pAKT expression in CIN and invasive cervical cancer tissues.
Consistent with our in vitro data, SCP3 expression was positively
associated with pAKT expression in both CIN (P,0.001) and
cervical cancer (P=0.010) (Table 1). Even when SCP3 expression
was compared with levels of pAKT using Spearman nonpara-
metric correlation test, SCP3 expression was significantly associ-
ated with pAKT expression in both CIN (Spearman’s rho= 0.322,
P,0.001) and cancer specimens (Spearman’s rho= 0.197,
P=0.010). Together, these data indicated that SCP3 mediates
an oncogenic phenotype of cervical cancer cells through an AKT-
dependent pathway. Collectively, the results of this study provide
the first molecular and cellular evidence of AKT-dependent
oncogenic properties of hSCP3, which may serve as a novel
therapeutic target for cervical cancer therapy.
Supporting Information
Figure S1 Evaluation of SCP3 and pAKT IHC staining.
Representative immunohistochemical staining images of the
staining intensity (A) weak staining, 1; (B) moderate staining, 2;
or (C) strong positive staining in most cells, 3 and the percentage of
positive stained epithelial cells (D) 1–25% cells staining positive, 1;
(E) 26–50% cells staining positive, 2; (F) 51–75% cells staining
positive, 3; or (G) more than 75% cells staining positive, 4. Scale
bar: 30 mm (A–C), 100 mm (D–G).
(TIF)
Figure S2 Members of the Cor1 family have oncogenic
potential. (A) NIH3T3 cells retrovirally transduced with pMSCV
vector encoding either no insert (NIH3T3/no insert), mSCP3
(NIH3T3/mSCP3), mXMR (NIH3T3/mXMR), or mXLR
(NIH3T3/mXLR) were analyzed for cellular expression of Cor1
members tagged with Flag by Western blot. (B) In vitro growth
curves of NIH3T3 cells expressing each of the Cor1 members.
NIH3T3/no insert cells were used as a control. The cells were
counted after trypan blue staining to exclude dead cells. (C) Bar
graph representing the number of colonies with a diameter greater
than 2 mm in soft agar. (D) Representative colony images of each
group (scale bar: 1 mm). (E) Tumorigenicity of NIH3T3 cells
expressing each of the Cor1 members. Balb/c Nude (n = 5) mice
were inoculated subcutaneously with 16105 cells/mouse using
NIH3T3/no insert, NIH3T3/mSCP3, NIH3T3/mXMR, or
NIH3T3/mXLR cells. Tumor volumes were measured beginning
28 days after tumor inoculation. (F) Representative tumor images
of each group.
(TIF)
Figure S3 Oncogenesis by Cor1 family is AKT-dependent. (A)
Western blot analysis of levels of pAKT in NIH3T3/no insert,
NIH3T3/mSCP3, NIH3T3/mXMR, or NIH3T3/mXLR cells.
(B) Soft agar colony-forming capacity of NIH3T3/mXLR cells in
the presence of API2 (Akt inhibitor), PD98059 (Erk inhibitor) or
SB203580 (p38 inhibitor); (Left) Representative colony images of
each group; (Right) Bar graph representing the number of colonies
with a diameter greater than 2 mm in soft agar (scale bar: 1 mm).
(C) Western blot analysis of levels of pAKT in NIH3T3/hSCP3
cells transfected with siRNA targeting GFP or AKT (siGFP or
siAKT) to confirm the reduction of protein levels of AKT. (D) In
vitro growth curves and (E) in vitro soft agar colony formation of
siGFP or siAKT-transfected NIH3T3/mXLR cells. Error bars
represent the mean 6 SD.
(TIF)
Figure S4 Relationship between the SCP3 and pAKT expres-
sion in CIN (left panel) and cancer (right panel) samples. The
values of pAKT IHC expressions were plotted on the y-axis
against the IHC scores of SCP3 on the x-axis.
(TIF)
Table S1 Characteristics of Patients.
(DOCX)
Table S2 Expression of SCP3 and pAKT in relation to
clinicopathological characteristics in IHC analysis.
(DOCX)
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